Lonza's 2000-litre facility in US meets demand for mid-scale microbial manufacture

Swiss pharmaceutical company Lonza has started up its high-titre 2000-litre microbial manufacturing train in Hopkinton, MA (USA). A flexible purification area capable of accommodating complex, high titre and throughput-optimised purification processes complements the 2000-litre fermentation train.

Lonza has revamped the entire Hopkinton site leading to improved infrastructure reliability (utilities, electricity, waste streams) and increased operational efficiency while meeting cGMP requirements. A strong r&d organisation complements the new manufacturing and infrastructure capabilities.

"Now we can offer our customers a state-of-the-art microbial manufacturing facility which allows for tailor-made multi-product operations," said Dr Juerg Burger, head of Lonza's global microbial operation. "This 2000-litre mid-size facility is an ideal complement to our existing microbial capacities, thus providing our customers the full range from small to large scale."

Lonza is a global leader in the production and support of active pharmaceutical ingredients both chemically and biotechnologically.